



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Attorney Docket Number

38005-0087

Complete if Known

Application Number	09/256,237
Filing Date	February 24, 1999
First Named Inventor	Heinrich HEIDTMANN et al.
Group Art Unit	1642
Examiner Name	M. Davis

TECH CENTER 1600/2900

APR 03 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
YD	C01	DEBORAH DEFEO-JONES et al., "A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo", Nature Medicine, November 2000, pp. 1248-1252, Vol. 6, No. 11	
	C02	SAMUEL R. DENMEADE et al., "Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen", Cancer Research, June 15, 1998, pp. 2537-2540, Vol. 58	
	C03	SAMUEL R. DENMEADE et al., "Specific and Efficient Peptide Substances for Assaying the Proteolytic Activity of Prostate-specific Antigen", Cancer Research, November 1, 1997, pp. 4924-4930, Vol. 57	
	C04	DENMEADE, SR et al., "Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer", Cancer J. Sci. Am, May 1998, 4 Supl. 1:S15-21	
	C05	JUDAH FOLKMAN, "Angiogenesis in cancer, vascular, rheumatoid and other disease", Nature Medicine, 1995, pp. 27-31, Vol. 1, No. 1	
	C06	JUDAH FOLKMAN, "Clinical Applications of Research on Angiogenesis", The New England Journal of Medicine, December 28, 1995, PP. 1757-1763, Vol. 333, No. 26	
	A07	JUDAH FOLKMAN et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia", Nature, May 4, 1989, pp. 58-61, Vol. 339	
	A08	BRUCE FURIE et al., "The Molecular Basis of Blood Coagulation", Cell, May 20, 1988, pp. 505-518, Vol. 53	
	A09	XIANMING HUANG et al., "Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature", Science, January 24, 1997, pp. 547-550, Vol. 275	
	A10	KHAN SR, et al., "In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts", Prostate, September 2000; 45(1):80-3	
	A11	JARI LEINONEN et al., "Complex Formation Between PSA Isoenzymes and Protease Inhibitors", The Journal of Urology, March 1996, pp. 1099-1103, Vol. 155	
	A12	HANS LILJA et al., "Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with α_1 -Antichymotrypsin", Clin. Chem., 1991, pp. 1618-1625, Vol. 37, No. 9	
	A13	LANCE ALLEN LIOTTA et al., "Quantitative Relationships of Intravascular Tumor Cells, Tumor Vessels, and Pulmonary Metastases following Tumor Implantation", Cancer Research, May 1974, pp. 997-1004, Vol. 34	
	A14	KENNETH W.K. WATT et al., "Human prostate-specific antigen: Structural and functional similarity with serine proteases", Proc. Natl. Acad. Sci. USA, May 1986, pp. 3166-3170, Vol. 83	

Examiner Signature

M. T. Davis

Date Considered

05/01/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

tion Act of 1995, no persons are required to re-

Attachment # 27

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/256,237
Filing Date	February 24, 1999
First Named Inventor	Heinrich HEIDTMANN et al.
Group Art Unit	1642
Examiner Name	Minh Tam B. Davis
Attorney Docket Number	38005-0087

OCT 18 2002

RECEIVED

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

M. T. Davis

Date Considered

05/05/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

of 2

Complete if Known	
Application Number	09/256,237
Filing Date	February 24, 1999
First Named Inventor	Heinrich HEIDTMANN et al.
Group Art Unit	1642
Examiner Name	M. Davis
Attorney Docket Number	38005-0087

OCT 18 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Signature	M. T. Davis	Date Considered	05/05/03
--------------------	-------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.